It’s called "Shifting the Needle."
Pharmaceutical giant Bayer is promoting eye health awareness among diabetic patients through a new advocacy campaign.
The effort follows a Bayer-funded study that found that diabetic patients “are waiting too long to discuss vision problems with their doctors,” FiercePharma reports.
The effort is geared toward both patients and healthcare professionals. Bayer sells the drug Eylea to treat diabetic retinopathy in people who have diabetic macular edema, FiercePharma notes.
The research, called the DR Barometer Study, involved the International Federation on Ageing, the International Agency for the Prevention of Blindness and the International Diabetes Federation.
According to the DR Barometer website: “A growing of voices in the fields of aging, diabetes and vision has joined in solidarity under the banner of DR Barometer: Shifting the Needle to call for urgent policy actions for diabetes-related eye health.”
Read more at FiercePharma